The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.